{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:23:55Z","timestamp":1791235435622,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100030970","name":"Janssen-Cilag Limited","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030970","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>With 20\u201340% of patients who have inflammatory bowel disease (IBD) not responding to therapy, resource use and costs can be high. We performed a descriptive analysis of health-care data for IBD management in the National Health Service to explore potential areas for improvement.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this exploratory study, we analysed real-world data from the Discover dataset for adults with a diagnosis of incident IBD recorded in northwest London, UK, between 31 March, 2016, and 31 March, 2020. We compared mean visit numbers and primary and secondary care costs per patient to examine resource use and costs for active disease versus remission.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 7,733 patients (5,872 with ulcerative colitis [UC], 1,427 with Crohn\u2019s disease [CD], and 434 with codes for both [termed IBD-undefined in this study]). Remission was recorded in 19,218 (82%) of 23,488 observations for UC, 4,686 (82%) of 5,708 for CD, and 1,122 (65%) for IBD-undefined observations. Health-care resource use was significantly higher with active disease in all settings except primary care for UC. Total health-care costs were greater with active disease than remission for all diagnoses (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). The main driver of costs was inpatient hospital care among those with active disease; elective inpatient costs were high among patients with UC and IBD-undefined in remission.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Higher health-care resource use and costs were observed with active disease, which underscores the importance of early induction and maintenance of remission in UC and CD. Updated strategies that incorporate treat to target may offer cost benefits by the offsetting of biologic drug costs with a reduction in costly inpatient hospital stays.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This trial was not registered as it used pseudonymised retrospective data.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-024-03559-3","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T11:45:08Z","timestamp":1735559108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Health-care resource use and costs associated with inflammatory bowel disease in northwest London: a retrospective linked database study"],"prefix":"10.1186","volume":"24","author":[{"given":"Zia","family":"UI-Haq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz","family":"Causin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahereh","family":"Kamalati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durgesh","family":"Kahol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trishan","family":"Vaikunthanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naila","family":"Arebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"issue":"4","key":"3559_CR1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.pop.2017.07.010","volume":"44","author":"T Sairenji","year":"2017","unstructured":"Sairenji T, Collins KL, Evans DV. An Update on Inflammatory Bowel Disease. Prim Care. 2017;44(4):673\u201392.","journal-title":"Prim Care"},{"issue":"5","key":"3559_CR2","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1080\/00365520601076124","volume":"42","author":"M Henriksen","year":"2007","unstructured":"Henriksen M, Jahnsen J, Lygren I, Aadland E, Schulz T, Vatn MH, et al. Clinical course in Crohn\u2019s disease: Results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol. 2007;42(5):602\u201310.","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"3559_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/00365520802600961","volume":"44","author":"IC Solberg","year":"2009","unstructured":"Solberg IC, Lygren I, Jahnsen J, Aadland E, H\u00f8ie O, Cvancarova M, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44(4):431\u201340.","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"3559_CR4","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/ibd\/izx100","volume":"24","author":"SR Knowles","year":"2018","unstructured":"Knowles SR, Graff LA, Wilding H, Hewitt C, Keefer L, Mikocka-Walus A. Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses\u2014Part I. Inflamm Bowel Dis. 2018;24(4):742\u201351.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"3559_CR5","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.crohns.2014.03.005","volume":"8","author":"S L\u00f6nnfors","year":"2014","unstructured":"L\u00f6nnfors S, Vermeire S, Greco M, Hommes D, Bell C, Avedano L. IBD and health-related quality of life \u2014 Discovering the true impact. J Crohn\u2019s Colitis. 2014;8(10):1281\u20136.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"5","key":"3559_CR6","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/MIB.0000000000001060","volume":"23","author":"WW IsHak","year":"2017","unstructured":"IsHak WW, Pan D, Steiner AJ, Feldman E, Mann A, Mirocha J, et al. Patient-Reported Outcomes of Quality of Life, Functioning, and GI\/Psychiatric Symptom Severity in Patients with Inflammatory Bowel Disease (IBD). Inflamm Bowel Dis. 2017;23(5):798\u2013803.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"3559_CR7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","volume":"7","author":"J Burisch","year":"2013","unstructured":"Burisch J, Jess T, Martinato M, Lakatos PL, on behalf of ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. J Crohn\u2019s Colitis. 2013;7(4):322\u201337.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"2","key":"3559_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10620-012-2371-5","volume":"58","author":"MD Kappelman","year":"2013","unstructured":"Kappelman MD, Moore KR, Allen JK, Cook SF. Recent Trends in the Prevalence of Crohn\u2019s Disease and Ulcerative Colitis in a Commercially Insured US Population. Dig Dis Sci. 2013;58(2):519\u201325.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"3559_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","volume":"5","author":"S Alatab","year":"2020","unstructured":"Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17\u201330.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3559_CR10","unstructured":"Crohn\u2019s, Colitis UK. New research shows over 1 in 123 people in UK living with Crohn\u2019s or Colitis [Internet]. 2022 [cited 2022 Nov 2]. https:\/\/crohnsandcolitis.org.uk\/news-stories\/news-items\/new-research-shows-over-1-in-123-people-in-uk-living-with-crohn-s-or-colitis"},{"issue":"7","key":"3559_CR11","doi-asserted-by":"publisher","first-page":"e036584","DOI":"10.1136\/bmjopen-2019-036584","volume":"10","author":"J Pasvol thomas","year":"2020","unstructured":"Pasvol thomas J, Horsfall L, Bloom S, Segal AW, Sabin C, Field N, et al. Incidence and prevalence of inflammatory bowel disease in UK primary care: a population-based cohort study. BMJ Open. 2020;10(7):e036584.","journal-title":"BMJ Open"},{"issue":"1","key":"3559_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","volume":"18","author":"GG Kaplan","year":"2021","unstructured":"Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(1):56\u201366.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"3559_CR13","doi-asserted-by":"publisher","first-page":"e00128","DOI":"10.14309\/ctg.0000000000000128","volume":"11","author":"CA Siegel","year":"2020","unstructured":"Siegel CA, Yang F, Eslava S, Cai Z. Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn\u2019s Disease in the United States. Clin Transl Gastroenterol. 2020;11(2):e00128.","journal-title":"Clin Transl Gastroenterol"},{"issue":"12","key":"3559_CR14","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1093\/ibd\/izz059","volume":"25","author":"DR Berg","year":"2019","unstructured":"Berg DR, Colombel JF, Ungaro R. The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25(12):1896\u2013905.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"3559_CR15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/j.gastro.2017.10.034","volume":"154","author":"\u00c5H Everhov","year":"2018","unstructured":"Everhov \u00c5H, Halfvarson J, Myrelid P, Sachs MC, Nordenvall C, S\u00f6derling J, et al. Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden. Gastroenterology. 2018;154(3):518\u2013e52815.","journal-title":"Gastroenterology"},{"issue":"3","key":"3559_CR16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/flgastro-2014-100514","volume":"6","author":"N Ghosh","year":"2015","unstructured":"Ghosh N, Premchand P. A UK cost of care model for inflammatory bowel disease. Frontline Gastroenterol. 2015;6(3):169\u201374.","journal-title":"Frontline Gastroenterol"},{"issue":"7","key":"3559_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1365-2036.2010.04234.x","volume":"31","author":"RD Cohen","year":"2010","unstructured":"Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31(7):693\u2013707.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 3","key":"3559_CR18","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1\u2013106.","journal-title":"Gut"},{"issue":"1","key":"3559_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5009\/gnl14226","volume":"9","author":"SC Park","year":"2015","unstructured":"Park SC, Jeen YT. Current and Emerging Biologics for Ulcerative Colitis. Gut Liver. 2015;9(1):18\u201327.","journal-title":"Gut Liver"},{"issue":"12","key":"3559_CR20","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1155\/2002\/463015","volume":"16","author":"R Hilsden","year":"2002","unstructured":"Hilsden R. Funding the new biologics\u2013what can we learn from infliximab? The CCOHTA report: a gastroenterologist\u2019s viewpoint. Can J Gastroenterol. 2002;16(12):865\u20138.","journal-title":"Can J Gastroenterol"},{"issue":"2","key":"3559_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/MEG.0000000000000244","volume":"27","author":"G Pellino","year":"2015","unstructured":"Pellino G, Sciaudone G, Selvaggi F, Riegler G. Delayed diagnosis is influenced by the clinical pattern of Crohn\u2019s disease and affects treatment outcomes and quality of life in the long term: a cross-sectional study of 361 patients in Southern Italy. Eur J Gastroenterol Hepatol. 2015;27(2):175\u201381.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"11","key":"3559_CR22","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1038\/ajg.2013.248","volume":"108","author":"AM Schoepfer","year":"2013","unstructured":"Schoepfer AM, Dehlavi MA, Fournier N, Safroneeva E, Straumann A, Pittet V, et al. Diagnostic delay in Crohn\u2019s disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol. 2013;108(11):1744\u201353. quiz 1754.","journal-title":"Am J Gastroenterol"},{"issue":"35","key":"3559_CR23","doi-asserted-by":"publisher","first-page":"6474","DOI":"10.3748\/wjg.v23.i35.6474","volume":"23","author":"Dwon Lee","year":"2017","unstructured":"Lee Dwon, Koo JS, Choe JW, Suh SJ, Kim SY, Hyun JJ, et al. Diagnostic delay in inflammatory bowel disease increases the risk of intestinal surgery. WJG. 2017;23(35):6474\u201381.","journal-title":"WJG"},{"issue":"10","key":"3559_CR24","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/apt.12727","volume":"39","author":"DT Rubin","year":"2014","unstructured":"Rubin DT, Mody R, Davis KL, Wang C-C. Real\u2010world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn\u2019s disease. Aliment Pharmacol Ther. 2014;39(10):1143\u201355.","journal-title":"Aliment Pharmacol Ther"},{"key":"3559_CR25","doi-asserted-by":"publisher","first-page":"1756283X1775035","DOI":"10.1177\/1756283X17750355","volume":"11","author":"S Vermeire","year":"2018","unstructured":"Vermeire S, Gils A, Accossato P, Lula S, Marren A. Immunogenicity of biologics in inflammatory bowel disease. Th Adv Gastroenterol. 2018;11:1756283X17750355.","journal-title":"Th Adv Gastroenterol"},{"issue":"4","key":"3559_CR26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/MOG.0000000000000740","volume":"37","author":"NA Cohen","year":"2021","unstructured":"Cohen NA, Rubin DT. New Targets in Inflammatory Bowel Disease Therapy: 2021. Curr Opin Gastroenterol. 2021;37(4):357\u201363.","journal-title":"Curr Opin Gastroenterol"},{"issue":"5","key":"3559_CR27","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, D\u2019Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570\u201383.","journal-title":"Gastroenterology"},{"issue":"9","key":"3559_CR28","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1016\/j.cgh.2022.10.029","volume":"21","author":"S Singh","year":"2023","unstructured":"Singh S, Kim J, Luo J, Paul P, Rudrapatna V, Park S, et al. Comparative Safety and Effectiveness of Biologic Therapy for Crohn\u2019s Disease: A CA-IBD Cohort Study. Clin Gastroenterol Hepatol. 2023;21(9):2359\u2013e23695.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"3559_CR29","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as Induction and Maintenance Therapy for Crohn\u2019s Disease. N Engl J Med. 2013;369(8):711\u201321.","journal-title":"N Engl J Med"},{"issue":"13","key":"3559_CR30","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, O\u2019Brien CD, Zhang H, Johanns J, et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2019;381(13):1201\u201314.","journal-title":"N Engl J Med"},{"key":"3559_CR31","doi-asserted-by":"crossref","unstructured":"Xu TY, Guo LL, Wang P, Song J, Le YY, Viollet B et al. Chronic Exposure to Nicotine Enhances Insulin Sensitivity through \u03b17 Nicotinic Acetylcholine Receptor-STAT3 Pathway. Chellappan SP, editor. PLoS ONE. 2012;7(12):e51217.","DOI":"10.1371\/journal.pone.0051217"},{"key":"3559_CR32","unstructured":"Jenkin Tsui J. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn\u2019s disease? aog [Internet]. 2018 [cited 2023 Mar 22]; http:\/\/www.annalsgastro.gr\/files\/journals\/1\/earlyview\/2018\/ev-04-2018-01-AG3303-0253.pdf"},{"issue":"8","key":"3559_CR33","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1093\/ibd\/izab228","volume":"28","author":"NM Noor","year":"2022","unstructured":"Noor NM, Sousa P, Paul S, Roblin X, Early Diagnosis. Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD. Inflamm Bowel Dis. 2022;28(8):1254\u201364.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"3559_CR34","doi-asserted-by":"publisher","first-page":"e0185500","DOI":"10.1371\/journal.pone.0185500","volume":"12","author":"N Pillai","year":"2017","unstructured":"Pillai N, Dusheiko M, Burnand B, Pittet V. A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS ONE. 2017;12(10):e0185500.","journal-title":"PLoS ONE"},{"issue":"2","key":"3559_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2174\/0929867324666170406112304","volume":"26","author":"L Gulacsi","year":"2019","unstructured":"Gulacsi L, Pentek M, Rencz F, Brodszky V, Baji P, Vegh Z, et al. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. Curr Med Chem. 2019;26(2):259\u201369.","journal-title":"Curr Med Chem"},{"issue":"1","key":"3559_CR36","first-page":"657","volume":"20","author":"A Bottle","year":"2020","unstructured":"Bottle A, Cohen C, Lucas A, Saravanakumar K, Ul-Haq Z, Smith W, et al. How an electronic health record became a real-world research resource: comparison between London\u2019s Whole Systems Integrated Care database and the Clinical Practice Research Datalink. BMC Med Inf Decis Mak. 2020;20(1):657\u201372.","journal-title":"BMC Med Inf Decis Mak"},{"issue":"3","key":"3559_CR37","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2036.2009.04033.x","volume":"30","author":"K Bodger","year":"2009","unstructured":"Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn\u2019s disease: Markov cohort analyses incorporating United Kingdom patient\u2010level cost data. Aliment Pharmacol Ther. 2009;30(3):265\u201374.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"3559_CR38","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1053\/j.gastro.2024.01.041","volume":"166","author":"R Lujan","year":"2024","unstructured":"Lujan R, Buchuk R, Focht G, Yogev D, Greenfeld S, Ben-Tov A, et al. Early Initiation of Biologics and Disease Outcomes in Adults and Children With Inflammatory Bowel Diseases: Results From the Epidemiology Group of the Nationwide Israeli Inflammatory Bowel Disease Research Nucleus Cohort. Gastroenterology. 2024;166(5):815\u2013e82522.","journal-title":"Gastroenterology"},{"issue":"4","key":"3559_CR39","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/apt.18106","volume":"60","author":"RLM Nordestgaard","year":"2024","unstructured":"Nordestgaard RLM, Wewer MD, Malham M, Wewer V, Boysen T, Burisch J. Treatment of inflammatory bowel disease with steroid-sparing medications is age-dependent \u2013 Results from a Danish nationwide cohort study, 2000\u20132018. Aliment Pharmacol Ther. 2024;60(4):457\u201368.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"3559_CR40","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1186\/s12913-021-06816-3","volume":"21","author":"S Alulis","year":"2021","unstructured":"Alulis S, Vadstrup K, Olsen J, J\u00f8rgensen TR, Qvist N, Munkholm P, et al. The cost burden of Crohn\u2019s disease and ulcerative colitis depending on biologic treatment status \u2013 a Danish register-based study. BMC Health Serv Res. 2021;21(1):836.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"3559_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ibd\/izz104","volume":"26","author":"KT Park","year":"2020","unstructured":"Park KT, Ehrlich OG, Allen JI, Meadows P, Szigethy EM, Henrichsen K, et al. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn\u2019s & Colitis Foundation. Inflamm Bowel Dis. 2020;26(1):1\u201310.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"3559_CR42","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S2468-1253(20)30012-1","volume":"5","author":"J Burisch","year":"2020","unstructured":"Burisch J, Vardi H, Schwartz D, Friger M, Kiudelis G, Kup\u010dinskas J, et al. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. Lancet Gastroenterol Hepatol. 2020;5(5):454\u201364.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"3559_CR43","doi-asserted-by":"publisher","first-page":"e000191","DOI":"10.1136\/bmjgast-2017-000191","volume":"5","author":"A Ahmad","year":"2018","unstructured":"Ahmad A, Laverty AA, Alexakis C, Cowling T, Saxena S, Majeed A, et al. Changing nationwide trends in endoscopic, medical and surgical admissions for inflammatory bowel disease: 2003\u20132013. BMJ Open Gastroenterol. 2018;5(1):e000191.","journal-title":"BMJ Open Gastroenterol"},{"key":"3559_CR44","unstructured":"Colitis UK. Inflammatory bowel disease Spotlight Project 2017\u20132020: impact report [Internet]. 2020 [cited 2024 Feb 13]. http:\/\/s3-eu-west-1.amazonaws.com\/files.crohnsandcolitis.org.uk\/Health_Services\/Inflammatory_Bowel_Disease_Project_Impact_Report_0920_v3.pdf"},{"issue":"5","key":"3559_CR45","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S2468-1253(23)00003-1","volume":"8","author":"J Burisch","year":"2023","unstructured":"Burisch J, Zhao M, Odes S, De Cruz P, Vermeire S, Bernstein CN, et al. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2023;8(5):458\u201392.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3559_CR46","unstructured":"NICE. NICE real-world evidence framework [Internet]. National Institute for Health and Care Excellence; [cited 2024 Nov 20]. https:\/\/www.nice.org.uk\/corporate\/ecd9\/resources\/nice-realworld-evidence-framework-pdf-1124020816837"},{"issue":"6","key":"3559_CR47","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","volume":"18","author":"C Kapizioni","year":"2023","unstructured":"Kapizioni C, Desoki R, Lam D, Balendran K, Al-Sulais E, Subramanian S, et al. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource. J Crohns Colitis. 2023;18(6):790\u2013800.","journal-title":"J Crohns Colitis"},{"issue":"12","key":"3559_CR48","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.cgh.2007.09.002","volume":"5","author":"IC Solberg","year":"2007","unstructured":"Solberg IC, Vatn MH, H\u00f8ie O, Stray N, Sauar J, Jahnsen J, et al. Clinical Course in Crohn\u2019s Disease: Results of a Norwegian Population-Based Ten-Year Follow-Up Study. Clin Gastroenterol Hepatol. 2007;5(12):1430\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"3559_CR49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12962-018-0114-y","volume":"16","author":"A Hansson-Hedblom","year":"2018","unstructured":"Hansson-Hedblom A, Almond C, Borgstr\u00f6m F, Sly I, Enkusson D, Troelsgaard Buchholt A, et al. Cost-effectiveness of ustekinumab in moderate to severe Crohn\u2019s disease in Sweden. Cost Eff Resour Alloc. 2018;16(1):28.","journal-title":"Cost Eff Resour Alloc"},{"issue":"4","key":"3559_CR50","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/apt.15889","volume":"52","author":"H Khalili","year":"2020","unstructured":"Khalili H, Everhov \u00c5H, Halfvarson J, Ludvigsson JF, Askling J, Myrelid P, et al. Healthcare use, work loss and total costs in incident and prevalent Crohn\u2019s disease and ulcerative colitis: results from a nationwide study in Sweden. Aliment Pharmacol Ther. 2020;52(4):655\u201368.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"3559_CR51","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1097\/MIB.0000000000000763","volume":"22","author":"B Click","year":"2016","unstructured":"Click B, Ramos Rivers C, Koutroubakis IE, Babichenko D, Anderson AM, Hashash JG, et al. Demographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22(6):1442\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"3559_CR52","unstructured":"Scobie S, Spencer J, Raleigh V. Ethnicity coding in English health service datasets [Internet]. Nuffield Trust; 2021 [cited 2024 Nov 20]. https:\/\/www.nuffieldtrust.org.uk\/sites\/default\/files\/2021-06\/1622731816_nuffield-trust-ethnicity-coding-web.pdf"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03559-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03559-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03559-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T13:04:33Z","timestamp":1735563873000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03559-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3559"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03559-3","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"28 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for the use of the Discover Platform for research was secured from the NHS Health Research Authority in October 2018. The REC reference is 18\/WM\/0323 and the IRAS project ID is 253449. Ethics approval from an institutional review board was not sought as all data were anonymised.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DK was employed by Janssen-Cilag Ltd (a subsidiary of Johnson & Johnson) at the time that the study was conducted and currently owns Johnson & Johnson stock\/stock options. TV is currently employed by Janssen-Cilag Ltd (a subsidiary of Johnson & Johnson) and owns Johnson & Johnson stock\/stock options. NA has received grants and consultancy fees from Janssen, Lilly, Ferring and Abbvie. ZU-H, TK and CW declared no conflicts of interest. LC was employed by Janssen-Cilag Ltd (a subsidiary of Johnson & Johnson) at the time that the study was conducted. TK and ZU-H were employed by Imperial College Health Partners at the time that the study was conducted.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"480"}}